Denileukin diftitox Completed Phase 2 Trials for Malignant Lymphomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00138164Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00460109Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
NCT00003615Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma